Therapeutic Advances in Vaccines and Immunotherapy最新文献_第10页

Healthcare-associated infections: potential for prevention through vaccination. 医疗保健相关感染：通过接种疫苗进行预防的潜力。

Therapeutic Advances in Vaccines and Immunotherapy Pub Date : 2018-02-01 Epub Date: 2018-03-14 DOI: 10.1177/2515135518763183

E David G McIntosh

引用次数: 0

Bispecific antibodies in cancer immunotherapy. 癌症免疫治疗中的双特异性抗体。

Therapeutic Advances in Vaccines and Immunotherapy Pub Date : 2018-02-01 Epub Date: 2018-03-28 DOI: 10.1177/2515135518763280

Eva Dahlén, Niina Veitonmäki, Per Norlén

{"title":"Bispecific antibodies in cancer immunotherapy.","authors":"Eva Dahlén, Niina Veitonmäki, Per Norlén","doi":"10.1177/2515135518763280","DOIUrl":"https://doi.org/10.1177/2515135518763280","url":null,"abstract":"Following the clinical success of immune checkpoint antibodies targeting CTLA-4, PD-1 or PD-L1 in cancer treatment, bispecific antibodies are now emerging as a growing class of immunotherapies with potential to further improve clinical efficacy and safety. We describe three classes of immunotherapeutic bispecific antibodies: (a) cytotoxic effector cell redirectors; (b) tumor-targeted immunomodulators; and (c) dual immunomodulators. Cytotoxic effector cell redirectors are dominated by T-cell redirecting compounds, bispecific compounds engaging a tumor-associated antigen and the T-cell receptor/CD3 complex, thereby redirecting T-cell cytotoxicity to malignant cells. This is the most established class of bispecific immunotherapies, with two compounds having reached the market and numerous compounds in clinical development. Tumor-targeted immunomodulators are bispecific compounds binding to a tumor-associated antigen and an immunomodulating receptor, such as CD40 or 4-1BB. Such compounds are usually designed to be inactive until binding the tumor antigen, thereby localizing immune stimulation to the tumor environment, while minimizing immune activation elsewhere. This is expected to induce powerful activation of tumor-specific T cells with reduced risk of immune-related adverse events. Finally, dual immunomodulators are bispecific compounds that bind two distinct immunomodulating targets, often combining targeting of PD-1 or PD-L1 with that of LAG-3 or TIM-3. The rationale is to induce superior tumor immunity compared to monospecific antibodies to the same targets. In this review, we describe each of these classes of bispecific antibodies, and present examples of compounds in development.","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/2515135518763280","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36306489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 123

The influence of radiation in the context of developing combination immunotherapies in cancer. 辐射对开发癌症联合免疫疗法的影响。

Therapeutic Advances in Vaccines and Immunotherapy Pub Date : 2017-12-01 Epub Date: 2018-01-24 DOI: 10.1177/2051013617750561

Jamie Honeychurch, Timothy M Illidge

{"title":"The influence of radiation in the context of developing combination immunotherapies in cancer.","authors":"Jamie Honeychurch, Timothy M Illidge","doi":"10.1177/2051013617750561","DOIUrl":"10.1177/2051013617750561","url":null,"abstract":"In addition to tumouricidal activity, radiotherapy is now recognized to display potent immunostimulatory properties that can contribute to the generation of anti-cancer immune responses. Treatment with radiation can induce a variety of pro-immunogenic and phenotypic changes in malignant cells, and recalibrate the immune contexture of the tumour microenvironment, leading to enhanced activation of the innate immune system, and priming of tumour-specific T-cell immunity. The immune-dependent effects of radiotherapy provide a sound rationale for the development of combination strategies, whereby the immunomodulatory properties of radiation can be exploited to augment the activity of immunotherapeutic agents. Encouraged by the recent success of breakthrough therapies such as immune checkpoint blockade, and a wealth of experimental data demonstrating the efficacy of radiotherapy and immunotherapy combinations, the clinical potential of this approach is now being explored in numerous trials. Successful translation will require careful consideration of the most suitable dose and fractionation of radiation, choice of immunotherapy and optimal sequencing and scheduling regimen. Immunological control of cancer is now becoming a clinical reality. There is considerable optimism that the development of effective radiotherapy and immunotherapy combinations with the capacity to induce durable, systemic immunity will further enhance patient outcome and transform the future management of cancer.","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933534/pdf/10.1177_2051013617750561.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36306488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

It is time to accelerate building local vaccine adjuvant manufacturing capacity. 现在是加快建设当地疫苗佐剂生产能力的时候了。

Therapeutic Advances in Vaccines and Immunotherapy Pub Date : 2017-12-01 Epub Date: 2017-10-09 DOI: 10.1177/2051013617733259

Christopher B Fox

引用次数: 5